2010-23195. Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone-depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error.

FOR FURTHER INFORMATION CONTACT:

Diane Sullivan, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3210, Silver Spring, MD 20993, 301-796-9171.

SUPPLEMENTARY INFORMATION:

In FR Doc. 2010-8467, appearing on page 19213, in the Federal Register of Wednesday, April 14, 2010, the following correction is made:

1. On page 19213, in the third column, the heading “RIN 0910-AF92” is corrected to read “RIN 0910-AF93”.

Dated: September 13, 2010.

David Dorsey,

Acting Deputy Commissioner for Policy, Planning and Budget.